Drug Combination Details
| General Information of the Combination (ID: C50529) | |||||
|---|---|---|---|---|---|
| Name | Cystine NP Info | + | Tegafur Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Adenocarcinoma
[ICD-11: 2D40]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Experimental
Result(s) |
The chemotherapeutic action of tegafur (FT) against adenocarcinoma 755 in mice was markedly potentiated by oral administration of L-cysteine and L-cystine without increasing its toxicity. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Potentiation of the chemotherapeutic action of tegafur against solid adenocarcinoma 755 by combination with L-cystine. J Cancer Res Clin Oncol. 1986;111(3):187-90. | |||
